- Home
- PHAT
as 04-22-2025 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 339.8M | IPO Year: | 2019 |
| Target Price: | $22.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $19.71 | Next Earning Date: | 05-08-2025 |
| Revenue: | $55,252,000 | Revenue Growth: | 8001.47% |
| Revenue Growth (this year): | 202.23% | Revenue Growth (next year): | 113.81% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Molly | PHAT | CFO and CBO | Apr 7 '25 | Sell | $4.55 | 3,678 | $16,739.68 | 89,868 | |
| Parikh Asit | PHAT | Director | Mar 13 '25 | Buy | $4.42 | 10,000 | $44,200.00 | 85,500 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago
GlobeNewswire
6 days ago
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Zacks
15 days ago
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?
GlobeNewswire
19 days ago
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
21 days ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
21 days ago
Phathom Pharmaceuticals Names Steven Basta CEO
GlobeNewswire
21 days ago
Phathom Pharmaceuticals Announces Leadership Succession
GlobeNewswire
22 days ago
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.